Skip to content

APOTHEEK URSEL

Active
Private limited companyfounded 2010active for 16 yearsUrselseweg 259, 9910 Aalter, BelgiumKBO/BCE: BE 0827.005.865
Summary

APOTHEEK URSEL has been active since 2010 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €209,491 and a net result of €118,542. Equity is growing by about 6.2% per year across the filed financial years. Its solvency ranks better than 23% of 12,672 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).

Overview

Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€1.7mtotal assets 2025
Equity
€209,491
Profit
€118,542
Turnover not published (abbreviated format)
Financial health
85 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.3%
Structure
Parent
DEDEYNE BRUNO · 100%
2025 accounts 32 days early6 deeds in the Belgian Official Gazette
Why 85raises riskEquity €209,491 (12.3% of total assets)Sector: Retail trade (NACE 47)lowers riskSize: total assets €1.7mFigures for financial year 2025 (filed 29-06-2026)Show the evidence

Checked score

Score 2025
85 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 37% of its sector peers (NACE 47, micro)
Financial strength · tick = 2024
Weak
Solvency 37-1
equity 12.3% of total assets
Liquidity 17-6
short-term debt 70.8% · cash 4.0%
Profitability 77-3
return on assets 6.9%
Bankruptcy probability, 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%

About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,231 companies, NACE 47, micro)
Last 24 months 11-2024: 0.3% 12-2024: 0.3%● unchanged vs 11-2024 01-2025: 0.3%● unchanged vs 12-2024 02-2025: 0.3%● unchanged vs 01-2025 03-2025: 0.3%● unchanged vs 02-2025 04-2025: 0.3%● unchanged vs 03-2025 05-2025: 0.3%● unchanged vs 04-2025 06-2025: 0.4%▲ +0.1 percentage points vs 05-2025 07-2025: 0.6%▲ +0.2 percentage points vs 06-2025 08-2025: 0.2%▼ -0.4 percentage points vs 07-2025 09-2025: 0.2%● unchanged vs 08-2025 10-2025: 0.2%● unchanged vs 09-2025lowest value 11-2025: 0.2%● unchanged vs 10-2025lowest value 12-2025: 0.2%● unchanged vs 11-2025lowest value 01-2026: 0.2%● unchanged vs 12-2025lowest value 02-2026: 0.2%● unchanged vs 01-2026 03-2026: 0.2%● unchanged vs 02-2026 04-2026: 0.2%● unchanged vs 03-2026 05-2026: 0.3%▲ +0.1 percentage points vs 04-2026 06-2026: 0.3%● unchanged vs 05-2026 07-2026: 0.4%▲ +0.1 percentage points vs 06-2026 08-2026: 0.7%▲ +0.3 percentage points vs 07-2026 09-2026: 0.9%▲ +0.2 percentage points vs 08-2026highest value 10-2026: 0.3%▼ -0.6 percentage points vs 09-2026
Credit of up to €17,000 on 30-day terms is acceptable
Liquidity insufficient (current ratio 0.34, compared with 0.3 in 2024, below 1; short-term debt: 70.8% and cash: 4% of total assets), and 87.7% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 29% on solvency, 16% on liquidity, 66% on profitability and 37% on growth.

The bankruptcy probability was computed on 24-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises riskneutral
lowers risk · Size: total assets €1.7m
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
raises risk · Equity €209,491 (12.3% of total assets)
NBB · annual accounts
raises risk · Sector: Retail trade (NACE 47)
KBO
lowers risk · Figures for financial year 2025 (filed 29-06-2026)
NBB · annual accounts
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 23% of 12672 sector peers (2025).
NBB · sector comparison
Position among 12672 sector peers
Solvency
better than 23%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-06-2026, 32 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
32 days early
2024
14 days early
2023
5 days early
2022
2 days early
2021
4 days early
2020
24 days late
2019
10 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 3 days before the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 27 July (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
25-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · abbreviated…
  2. Annual accounts filedfinancial year 2024 · abbreviated…
  3. Highest result from 2018 to 2025net €144,177 ▲37%

Key points

  • Positive: 8 profitable years in a rowprofit 2025: €118,542 8 years View
  • Controlled by DEDEYNE BRUNO 100% View
  • Positive: Filed on time since financial year 2021accounts within the deadline every year 5 years View

By topic

Financials

Financial year
2025
Total assets
€1.7m
Profit
€118,542
Solvency
12.3%
Total assets▲ 3.6%
Net result
20182025
Go to Financials

Timeline

Events
19
Since
2012
Next accounts
by 31-07-2027
  1. 26-07-2024Annual accounts filed
  2. 29-07-2023Annual accounts filed
  3. 27-07-2022Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
28-06-2010
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Key facts about APOTHEEK URSEL

What is the company number of APOTHEEK URSEL?
0827.005.865. In Belgium the VAT number is the company number with BE in front: BE 0827.005.865.
Where is APOTHEEK URSEL based?
The registered office is at Urselseweg 259, 9910 Aalter.Company details
What does APOTHEEK URSEL do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of APOTHEEK URSEL?
Private limited company (BV).
When was APOTHEEK URSEL founded?
On 28-06-2010.
Is APOTHEEK URSEL still active?
Yes, APOTHEEK URSEL is an active enterprise in the KBO register.
What is the turnover of APOTHEEK URSEL?
Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.Financials
Is APOTHEEK URSEL profitable?
In financial year 2025, APOTHEEK URSEL made a profit of €118,542.
Where can I find the annual accounts of APOTHEEK URSEL?
APOTHEEK URSEL filed 15 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of APOTHEEK URSEL due?
By 31-07-2027, for financial year 2026.Timeline

Companies related to APOTHEEK URSEL

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.